INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET -amplified NSCLC and first-line osimertinib resistance.

Autor: F Smit E; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Dooms C; Department of Respiratory Diseases & Respiratory Oncology Unit, University Hospitals Leuven, Leuven, Belgium., Raskin J; Department of Pulmonology & Thoracic Oncology, Antwerp University Hospital (UZA), Edegem, Belgium., Nadal E; Department of Medical Oncology, Catalan Institute of Oncology, L'Hospitalet, Barcelona, Spain., Tho LM; Department of Oncology, Pantai Hospital, Kuala Lumpur, Malaysia., Le X; Department of Thoracic Head & Neck Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Mazieres J; CHU de Toulouse, Institut Universitaire du Cancer, Toulouse, France., S Hin H; Hospital Tengku Ampuan Afzan, Pahang, Malaysia., Morise M; Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan., W Zhu V; University of California Irvine, Chao Family Comprehensive Cancer Center, Orange, CA, USA., Tan D; Division of Medical Oncology, National Cancer Centre Singapore, Singapore., H Holmberg K; EMD Serono Research & Development Institute, Inc., MA, USA, an affiliate of Merck KGaA., Ellers-Lenz B; Department of Biostatistics, Merck Healthcare KGaA, Darmstadt, Germany., Adrian S; Global Clinical Development, Merck Healthcare KGaA, Darmstadt, Germany., Brutlach S; Late Stage Development Operations, Merck Healthcare KGaA, Darmstadt, Germany., Schumacher KM; Global Clinical Development, Merck Healthcare KGaA, Darmstadt, Germany., Karachaliou N; Global Clinical Development, Merck Healthcare KGaA, Darmstadt, Germany., Wu YL; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China.

Publikováno v: Future oncology (London, England) [Future Oncol] 2022 Mar; Vol. 18 (9), pp. 1039-1054. Date of Electronic Publication: 2021 Dec 17.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Unlocking the potential of mesoporous silica nanoparticles in breast cancer treatment.

Autor: Thapa, Riya¹ (AUTHOR), Ali, Haider² (AUTHOR), Afzal, Obaid³ (AUTHOR), Bhat, Asif Ahmad¹ (AUTHOR), Almalki, Waleed Hassan⁴ (AUTHOR), Alzarea, Sami I.⁵ (AUTHOR), Kazmi, Imran⁶ (AUTHOR), Altamimi, Abdulmalik Saleh Alfawaz² (AUTHOR), Jain, Neha⁷ (AUTHOR), Pandey, Manisha⁸ (AUTHOR), Fuloria, Neeraj Kumar⁹ (AUTHOR), Sekar, Mahendran¹⁰ (AUTHOR), Meenakshi, Dhanalekshmi Unnikrishnan¹¹ (AUTHOR), Jakhmola, Vikash¹² (AUTHOR), Singh, Sachin Kumar^13,14 (AUTHOR), Dua, Kamal^14,15 (AUTHOR), Gupta, Gaurav^1,16 (AUTHOR) gauravpharma25@gmail.com

Publikováno v: Journal of Nanoparticle Research. Aug2023, Vol. 25 Issue 8, p1-28. 28p.

The Manufacture of Xeno- and Feeder-Free Clinical-Grade Human Embryonic Stem Cell Lines: First Step for Cell Therapy.

Autor: Souralova, Tereza^1,2 (AUTHOR), Rehakova, Daniela^1,2,3 (AUTHOR), Jeseta, Michal⁴ (AUTHOR), Tesarova, Lenka^1,2 (AUTHOR), Beranek, Jindrich¹ (AUTHOR), Ventruba, Pavel⁴ (AUTHOR), Hampl, Ales^2,5 (AUTHOR), Koutna, Irena^1,2 (AUTHOR) irena.koutna@fnusa.cz

Publikováno v: International Journal of Molecular Sciences. Oct2022, Vol. 23 Issue 20, p12500-N.PAG. 15p.

Biodiesel production from waste cooking oil using KOH/HY-type nano-catalyst derived from silica sand.

Autor: Abdul-Kader, Huda A., Shakor, Zaidoon M., Sherhan, Bashir Y., Al-Humairi, Shurooq T., Aboughaly, Mohamed, Hazrat, M. A., Fattah, Islam Md Rizwanul

Publikováno v: Biofuels (17597269); May2024, Vol. 15 Issue 5, p527-543, 17p